

**4D Molecular Therapeutics, Inc.**  
5858 Horton Street, #455  
Emeryville, California 94608

December 8, 2020

**VIA EDGAR AND E-MAIL**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-6010

Attention: Ada Sarmento  
Suzanne Hayes  
Jenn Do  
Jeanne Baker

**Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-250150)**

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-250150) (the "**Registration Statement**") of 4D Molecular Therapeutics, Inc. (the "**Company**"). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on December 10, 2020, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Benjamin Potter at (650) 470-4809 or Phillip Stoup at (415) 391-0600.

Thank you for your assistance in this matter.

Very truly yours,

**4D MOLECULAR THERAPEUTICS, INC.**

By: /s/ August Moretti

August Moretti  
Chief Financial Officer

cc: David Kim, M.D., 4D Molecular Therapeutics, Inc.  
Alan C. Mendelson, Latham & Watkins LLP  
Benjamin A. Potter, Latham & Watkins LLP  
Phillip Stoup, Latham & Watkins LLP  
David Peinsipp, Cooley LLP  
Charles S. Kim, Cooley LLP  
Kristin VanderPas, Cooley LLP